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Abstract Rapid tests for diagnosis of influenza are
valuable assets in the management of influenza in pediatric
patients. However, test performance fluctuates with virus
subtypes. We assessed the test characteristics of Influenza-
top®, a rapid immunochromatographic influenza A and B
test, in detecting pandemic 2009 influenza A (H1N1) in
children up to 18 years of age, using reverse transcriptase
polymerase chain reaction (RT-PCR) as the gold standard.
Three hundred and one pediatric outpatients with influenza-
like illness were included into the study. Overall sensitivity
of Influenzatop® was 64% (95% confidence interval (CI)
56–71%) but increased to 92% (95% CI, 80–97%) when
performed between 24 and 48 h after onset of symptoms.
Positive Influenzatop® results among RT-PCR-positive
patients were associated with higher viral load. No
significant variation in test performance could be detected
when analyzed by age and high versus low prevalence
period. Overall test specificity was 99% (95% CI, 95–
100%); positive and negative predictive values were 98%
(95% CI, 93–99%) and 70% (95% CI, 63–76%), respec-
tively. Conclusion: Influenzatop® rapid influenza test is a
sound tool in the diagnosis of H1N1 in pediatric patients
when employed 24–48 h after onset of symptoms.
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Introduction
On April 29, 2009, the first pandemic (H1N1) 2009
influenza case was reported in Switzerland. In Geneva
canton, 2,377 cases were reported until December 2009 for
a total population of 453,292, and around 57% occurred in
the pediatric age group [16]. Often decisions about
treatment, prophylaxis, and infection control measures have
to be taken by the pediatric provider before real-time
reverse transcriptase polymerase chain reaction (RT-PCR)
results are available. A variety of rapid tests for the
diagnosis of influenza are at hand and they are used
routinely in children. For management of seasonal influen-
za in pediatric patients, rapid tests have been shown to
reduce prescription of laboratory test, radiographic studies,
and antibiotics [4, 10, 12]. However, their performance
fluctuates with virus subtypes and has indeed been reported
to be poorer for nonhuman strains [6, 17]. It is hence crucial
to understand the characteristics of commercial tests used
for detection of pandemic (H1N1) 2009 virus because it
will probably continue to circulate in the population in
addition to the seasonal strains in the coming years. We
initially used both of QuickVue Influenza A + B® test
(Quidel), a rapid test routinely used for rapid testing for
seasonal influenza in our pediatric department at the
University Children’s Hospital Geneva (HUG), as well as
Influenzatop® (ALL.DIAG, Strasbourg, France), a rapid
immunochromatographic influenza A and B test, for rapid
detection of pandemic (H1N1) 2009 virus in addition to
routine RT-PCR testing. After an initial subset of patients
has been identified, it appeared from published data and our
own experience that sensitivity of QuickVue® was low to
moderate [8]. In order to limit the number of nasal swab
samples to be collected for each patient, we hence decided
to only further assess the performance of Influenzatop® in
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our population. The objective of this analysis was to
characterize Influenzatop® (ALL.DIAG, Strasbourg,
France), a rapid immunochromatographic influenza A and
B test, in detecting the pandemic (H1N1) 2009 virus among
pediatric patients.
Materials and methods
Study population and testing strategy
Patients up to 18 years of age who were tested for
pandemic (H1N1) 2009 virus using both Influenzatop®
and RT-PCR between August 21 and December 16, 2009
were included. Information from two different patient
subpopulations were used: the first population consisted
of patients included into a pediatric H1N1 surveillance
study conducted at HUG; the second population was
composed of test results from routine testing at the Pediatric
Emergency Division of HUG and at 13 participating
outpatient sites. Inclusion criteria and testing procedure
were identical for all subgroups. At HUG, a total of 591
pediatric patients were tested for H1N1 between August
and December 2009; 216 cases were confirmed positive
(Fig. 1). The peak of the epidemic in Geneva was observed
in November 2009 [16]. After November 21, 2009, the
Swiss pediatric H1N1 consortium recommended discontin-
uation of routine testing for pandemic (H1N1) 2009 virus.
Testing was subsequently limited to at-risk patients present-
ing influenza-like illness (ILI) as defined as fever ≥38°C plus
upper or lower respiratory symptoms. At-risk categories
were defined as follows: patients with severe or rapidly
aggravating symptoms; patients hospitalized for respiratory
infections; patients <12 months of age; patients with
personal risk factors such as chronic cardiac conditions,
severe asthma, cystic fibrosis, neuromuscular disease, and
immunodeficiency; infants <2 years of age born <33 weeks
of gestation or with birth weight <1,500 g; and patients in
close contact with at-risk patients such as infants <6 months
of age and pregnant women.
Sample collection and testing
For each patient, two specimens were collected by trained
physicians. One foam-tipped nasal swab provided by the
manufacturer was immediately tested with the Influenzatop®
assay (ALL.DIAG, Strasbourg, France) according to the
manufacturer’s protocol [1]. One additional nasopharyngeal
swab was placed in a viral transport medium, stored at 4°C,
and sent off the same day for testing using RT-PCR.
InfACDC, a protocol for identification and characterization
of the pandemic 2009 influenza A (H1N1) virus strain
provided by the Centers for Disease Control and Prevention
(CDC), was used [19]. The threshold for detection of
fluorescence above background was determined. For semi-
quantitative comparison of the amount of RNA template, i.e.,
viral load, the cycle threshold (Ct) of samples using InfACDC
was compared. Ct is the cycle at which the fluorescence from
a sample crosses the threshold for detection. Ct is thus
inversely related to viral load.
Data analysis
The sensitivities, specificities, positive predictive values
(PPV), and negative predictive values (NPV) of Influenza-
top® were calculated using RT-PCR for pandemic (H1N1)
2009 virus as the gold standard test; 95% confidence (95%
CI) intervals for proportions were produced with the Wilson
score method [11]. Differences in proportions among
subgroups were analyzed using chi-square tests. For
normally distributed variables, difference in mean viral
load between subgroups was assessed by ANOVA. For
prediction of sensitivity, covariates were compared between
Influenzatop®-negative and -positive patients within PCR-
positive samples. Chi-square tests were used for categorical
variables and t test for Ct. Logistic regression was
performed to study independent influence of various factors
on sensitivity. Ct was entered as a continuous variable
whereas duration of symptoms and age were categorized.
The final model was obtained through backward selection
of variables displayed in Table 3 using the likelihood ratio
test at the p<0.10 level. The performance of the predictive
model was illustrated by the receiver-operating characteris-
tic curve, as well as by sensitivity and specificity. All
statistical tests are two-tailed and a p value of 0.05 was
considered statistically significant. All computations were
performed using SPSS version 15.0 (SPSS Inc.) and Excel
2003 (Microsoft Inc.). Informed consent was obtained at
inclusion from patients participating in the H1N1 surveil-
lance study (n=83). For the 116 patients tested routinely at
HUG, consent was asked retrospectively via telephone
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interviews—4 of 116 patients refused participation in the
study. This study was approved by the ethical committee of
HUG. For patients included from routine testing at the 13
pediatric outpatient sites (n=94), anonymous data were sent
to the investigators for analysis. The study was also
approved by the ethical committee of Geneva County.
Results
Characteristics of the study population
Three hundred and one patients from the H1N1 surveillance
study (n=84, 27.9%) and from routine testing at HUG as
well as 13 outpatient sites (n=217, 72.1%) were included in
the study. The age range of the patients tested was 7 days to
18 years (mean 6.8 years, SD 4.8 years, median 6.06 years);
50 patients (16.6%) were under 24 months of age. Age and
sex characteristics were similar for the two patient
subpopulations; patients tested in the context of H1N1
surveillance study presented slightly later into the illness
(Table 1).
Performance of Influenzatop®
RT-PCR results for pandemic (H1N1) 2009 virus were
positive in 164 samples (54%). Table 2 displays both the
overall test characteristics for Influenzatop® for the detection
of pandemic (H1N1) 2009 virus, as well as stratified by
patient subpopulation, age, duration of symptoms, and
prevalence phase. In our patient population, Influenzatop®
had an overall sensitivity, specificity, PPV, and NPV of 64%
(95% CI, 56–71%), 99% (95% CI, 95–1.00%), 98% (95%
CI, 93–99%), and 70% (95% CI, 63–76%), respectively. As
for the different patient subgroups, Influenzatop® showed a
higher sensitivity and NPV in patients tested during routine
testing: 69% versus 53% (chi-square 4.13 (p=0.042)) and
76% versus 54% (overall chi-square 7.55 (p=0.006)),
respectively. No significant difference in specificity nor
PPV could be detected: chi-square 0.48 (p=0.49) and 0.36
(p=0.55). Sensitivity, specificity, and PPV were not signif-
icantly different across age strata: overall chi-square—3.98
(p=0.14), 3.03 (p=0.22), and 0.41 (p=0.81), respectively.
However, a significant difference was found for NPV (overall
chi-square 17.70, p=0.001): NPV was greater for children
aged <1 and 1–5 years when compared to patients >5 years of
age (88% and 78% versus 56%; chi-square 20.49 (p<0001),
9.73 (p=0.007), respectively). As for the duration of
symptoms, sensitivity was significantly greater when the
test was performed between 24 and 48 h after onset of
symptoms (92%) when compared to within the first 12 h
(35%, chi-square 21.78, p<0.0001), 12–24 h (66%, chi-
square 18.20, p=0.0004), and after 48 h (59%, chi-square
9.53, p=0.023). No significant difference in specificity
and PPV was detected when stratified by duration of
symptoms (overall chi-square 2.31 (p=0.55), and 0.54
(p=0.91), respectively). NPV was significantly greater
between 24 and 48 h after onset of symptoms (96%,
overall chi-square 11.78, p=0.008) when contrasted
to ≤12 h (66%, chi-square 8.71, p=0.03) and 12–24 h
(75%, chi-square 17.66, p=0.0005). The test performance
within the peak period of the epidemic (weeks 45–48) was
not different from that during weeks of lower prevalence
in terms of sensitivity, specificity, and PPV (chi-square
0.54 (p=0.46), 1.88 (p=0.17), and 0.48 (p=0.52), respec-
tively). A greater NPV was observed in weeks of lower
prevalence (93%) versus during the peak of the epidemic
(64%, chi-square 24.04, p<0.0001).
For prediction of the probability of testing positive with
Influenzatop® among RT-PCR-positive patients, hence an
indicator of sensitivity, binary logistic regression was
performed. The following variables (Table 3) were evalu-
ated for the development of the prediction model: age,
duration of symptoms, Ct, patient subgroup, as well as high
versus low prevalence season. These variables showed no
significant correlation. From these variables, duration of
symptoms and Ct made statistically significant contribution
to the prediction (Table 4). Receiver-operating characteris-
tic curve for the predictive model had an area under the
curve of 0.78 (95% CI, 0.73–0.84) with an optimal
sensitivity and specificity of 77% and 85%, respectively.
In terms of viral load, RT-PCR-positive samples that
yielded positive results in the rapid test reached threshold
after a mean of 22.97 cycles (SD±3.40). This contrasted
with a significantly greater Ct of 25.77 (SD±5.02) in the
rapid test-negative group. These results thus indicate an
Table 1 Characteristics of patients by subgroup
Variable H1N1 surveillance study (n=84) Routine testing (n=217) p value
Female sex (%) 45.2 42.4 0.65
Age (years, mean±SD) 6.5±4.4 6.9±4.9 0.52
Duration of symptoms (hours; mean±SD) 56.2±43.8 36.4±29.5 0.01
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increase in rapid test sensitivity with higher viral load
(Table 3). This was indeed confirmed when tested in the
logistic regression model where a decrease in Ct (hence
increase in viral load) was associated with an increase in
sensitivity (Table 4). Mean viral load among RT-PCR-
positive patients was lower >48 h after onset of symptoms
when compared to patients presenting between 12 and
24 h (Ct 26.6 versus 23.2, p=0.01; overall ANOVA F
3.37, p=0.02). No significant difference in mean viral load
across duration strata could be detected (ANOVA F 1.10,
p=0.36). Coherent with subgroup analysis (Table 2),
duration of symptoms was a predictor of sensitivity in
the logistic regression model; a strong positive association
was observed in the subgroup of 24–48 h post onset of
symptoms when compared to ≤12 h.
Discussion
This study is the first to evaluate the performance of
Influenzatop®, a rapid immunochromatographic influenza
A and B test, for detection of pandemic (H1N1) 2009 virus
Table 2 Test characteristics of Influenzatop® rapid test compared to RT-PCR
Number Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Overall 301 0.64 (0.56–0.71) 0.99 (0.95–1.00) 0.98 (0.93–0.99) 0.70 (0.63–0.76)
Patient population H1N1 surveillance study 84 0.53 (0.39–0.66) 0.97 (0.84–1.00) 0.97 (0.83–1.00) 0.54 (0.42–0.67)
Routine testing 217 0.69 (0.60–0.77) 0.99 (0.95–1.00) 0.99 (0.93–1.00) 0.76 (0.68–0.82)
Age (years) 0–1 50 0.62 (0.36–0.83) 1.00 (0.91–1.00) 1.00 (0.68–1.00) 0.88 (0.75–0.95)
1–5 67 0.45 (0.27–0.65) 1.00 (0.90–1.00) 1.00 (0.72–1.00) 0.78 (0.67–0.88)
>5 184 0.68 (0.59–0.75) 0.96 (0.88–0.99) 0.97 (0.92–0.99) 0.56 (0.46–0.66)
Duration of symptoms (hours) ≤12 52 0.35 (0.19–0.55) 1.00 (0.88–1.00) 1.00 (0.68–1.00) 0.66 (0.51–0.78)
>12≤24 108 0.66 (0.54–0.76) 0.97 (0.86–1.00) 0.98 (0.89–1.00) 0.75 (0.61–0.85)
>24≤48 67 0.92 (0.80–0.97) 0.96 (0.82–0.99) 0.97 (0.86–0.99) 0.96 (0.74–0.97)
>48 61 0.59 (0.36–0.78) 1.00 (0.90–1.00) 1.00 (0.72–1.00) 0.84 (0.70–0.92)
Prevalence Low 83 0.76 (0.55–0.89) 1.00 (0.94–1.00) 1.00 (0.81–1.00) 0.93 (0.84–0.97)
High (weeks 45–48) 180 0.69 (0.59–0.76) 0.97 (0.90–0.99) 0.97 (0.91–0.99) 0.64 (0.55–0.73)
Table 3 Characteristics of RT-PCR-positive patients
Variable Influenzatop® positive (n=59), % Influenzatop® negative (n=105), % p value
Total 63.9 36.1
Female sex 40.0 52.5 0.12
Age (years) 0.50a
≤2 11.4 10.2
>2≤6 17.1 25.4
>6≤10 31.4 33.9
>10 40.0 30.5
Duration of symptoms (hours) <0.0001a
≤12 7.9 26.8
>12≤24 46.5 42.9
>24≤48 35.6 5.4
>48 9.9 25.0
High prevalence period
(weeks 45–48) 83.8 83.1 0.90
H1N1 surveillance study population 26.7 42.4 0.53
Ct (mean±SD) 22.97±3.40 25.77±5.02 <0.001
a Chi-square distribution across entire category
514 Eur J Pediatr (2011) 170:511–517
in children as compared to the standard of RT-PCR testing.
Rapid diagnostic tests are valuable tools in the management
of pediatric influenza cases as decisions often have to be
taken before PCR results are available. Understanding the
performance of commercially available tests in children is
thus crucial. We found that Influenzatop® was overall
moderately (64%) sensitive in detecting pandemic (H1N1)
2009 virus in children when compared to RT-PCR; NPV
was 70%. However, sensitivity increased to 92% when
performed between 24 and 48 h after onset of symptoms.
Overall test performance was hence not sufficient to
exclude H1N1 infection in all rapid test-negative patients.
At-risk patients at HUG with negative test results were thus
treated with neuraminidase inhibitors until RT-PCR results
were available. However, given the time-specific results of
this more detailed retrospective analysis, treatment could
have most likely been delayed in patients at moderate to
low risk of complicated infection presenting during the
illness phase of higher test sensitivity (48–72 h); this would
prevent overutilization of neuraminidase inhibitors in the
large number of patients that were PCR-negative. Influen-
zatop® is highly specific in detecting pandemic (H1N1)
2009 virus. Given these results, more expensive RT-PCR
testing in rapid test-positive patients may not be warranted.
Moreover, positive test results are especially useful in the
management of patients presenting with febrile illness that
are at low risk for bacterial co-infection (i.e., most patients
above 3 months of age). On site confirmation of infection
with pandemic (H1N1) 2009 virus in this patient group
could prevent overuse of antibiotics. On the other hand,
rapid testing in patients that are not eligible for RT-PCR
testing allows considering antiviral treatment with neur-
aminidase inhibitor. Treatment during the first 2 days of
symptoms has been shown to shorten influenza symptoms
and prevent lower respiratory tract complication in influ-
enza cases [9].
With regards to other commercial tests—although
comparison has to be qualified given that data were only
available from published data—we found that performance
of Influenzatop® was similar to that of QuickVue®—65%,
95% CI 58.5–71.4% but higher when compared to
BinaxNOW Influenza A&B® (Iverness Medical)—45%,
95% CI 43.3–46.3% [3, 8]. Sensitivity of Influenzatop®
was higher when performed between 24 and 48 h post onset
of symptoms compared to 74.2% (95% CI, 62–84.2) with
QuickVue® [8]. Sensitivity of Influenzatop® was about 7%
points higher contrasted to that estimated for direct
fluorescence antibody assay (57.3%) in pediatric patients
presenting with ILI [14]. In a large study assessing multiple
tests, sensitivities of BinaxNOW® and 3MA + B® as
compared to R-Mix culture for the detection of pandemic
(H1N1) 2009 virus were 9.6% and 40%, respectively.
However, in the latter study, the patient population included
adults (mean age 13.7 years, range 2 weeks to 97 years) [7].
Influenzatop® rapid test has neither been evaluated in
the pediatric population nor for pandemic (H1N1) 2009
virus. The test was reported by the manufacturer to be
98.3% sensitive and 90.1% specific in the detection of
influenza A in nasal swabs compared to viral isolation in
adults [1]. This divergence from test characteristics
observed in our study may be due to variation of
performance of rapid influenza detection tests by virus
subtype. Sensitivity of rapid tests has indeed been reported
to be poorer for the nonhuman pandemic (H1N1) 2009
viruses [6, 8, 14, 15, 17].
Viral load, as indicated by a lower number of RT-PCR
cycles needed to reach threshold (Ct), was a positive
predictor for true positive rapid test results when controlling
for age and duration of symptoms. This goes in line with
the results assessing the performance of BinaxNOW
Influenza A&B Rapid Test® in PCR-positive clinical
specimens [3, 5]. A positive correlation between sensitivity
and viral load has also been found in studies assessing rapid
tests during a regular influenza season [3].
Sensitivity was highest when the test was performed
between 24 and 48 h. This correlated with a higher viral
load in patients diagnosed 12–48 h post onset of symptoms
when compared to patients presenting after 48 h. This
observed variation in sensitivity is similar to that found for
QuickVue® which was found to be 59.7% sensitive on
day 1 compared to 76.9%, 79.5%, and 54.5% on days 2, 3,
and 4, respectively [3].
Additionally, in a study among adult patients, an
immunochromatographic rapid test was not found to be
Predictor b Wald OR 95% CI for OR p value
Ct −0.20 12.84 0.82 (0.73–0.91) <0.0001
Duration of symptoms (hours) 15.91 0.001
≤12 (reference) 1.00
>12≤24 1.35 5.14 3.84 (1.20–12.28) 0.023
>24≤48 3.70 15.23 40.33 (6.30–258.17) <0.0001
>48 1.01 1.86 2.75 (0.64–20.71) 11.78
Table 4 Results of binary
logistic regression model for
sensitivity
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sufficiently sensitive within the 24 h of fever onset owing
to low viral load [18]. However, in other studies among
adult patients, no significant difference between presenta-
tion within the first 24 h or later could be detected [3, 13].
In influenza volunteer challenge studies, peak viral load has
been reported 24–48 h following viral inoculation [2]. No
such data exist for children or elderly subjects, but
epidemiologic studies suggest that the natural history might
differ. It is possible that children are symptomatic at
relatively low viral loads [18]. Regarding the patient
population of this study, only a subgroup of at-risk patients
or patients with severe symptoms was tested after Novem-
ber 21, 2009. One might thus assume that viral load in this
group may already be high early into symptomatic illness
when compared to studies in the general pediatric popula-
tion. However, the majority of patients (81%) were
included before implementation of restricted testing and
our patient sample can hence still be considered represen-
tative for the general pediatric population.
There are several limitations to this study. The study was
performed in one region only and in a limited study
population. Testing in 19% of patients was limited to at-risk
patients and patients presenting with severe symptoms. Due
to this selection bias, prevalence of disease may be different
in the general pediatric population; the positive and
negative predictive values of any test are dependent on
the prevalence of disease. Additionally, these values would
diverge at different levels of circulation of seasonal
influenza and/or pandemic (H1N1) 2009. Performance of
Influenzatop® was compared to RT-PCR results with
InfACDC primers only; results may be different when
other primers are used as a reference standard.
In conclusion, regular assessment of test performance of
rapid influenza tests is essential given the continuous
antigenic drift of the influenza virus; performance may
vary by brand and by virus subtype. When comparing
Influenzatop® to that of QuickVue Influenza A + B® and
BinaxNOW Influenza A&B® assessed in previous studies,
performance of Influenzatop® appears comparable in
general but higher when employed between 24 and 48 h
post onset of symptoms [3, 8, 14]. Especially when
employed between 24 and 48 h after onset of symptoms,
Influenzatop® can be a valuable asset in the management of
pediatric H1N1 patients. Rapid testing may reduce overuse
of antibiotics and can be a helpful adjuvant in the decision
about treatment and follow-up of patients [12]. Starting
antiviral treatment with neuraminidase inhibitor during the
first 2 days of symptoms has been shown to shorten
influenza symptoms and prevent lower respiratory tract
complication in influenza cases [9]. In this subgroup,
Influenzatop® is a sound diagnostic alternative to the more
expensive RT-PCR which is not readily available in all
settings. Earlier on into the illness, negative results with
rapid tests are not sufficient to exclude infection. In these
cases, clinicians should make decision on the treatment,
prophylaxis, and preventive measures based on clinical
presentation, circulating subtypes, and their respective
antiviral susceptibility patterns, as well as economic
considerations.
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